专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009049257A2 PREDICTIVE MODELS AND METHODS FOR DIAGNOSING AND ASSESSING CORONARY ARTERY DISEASE 审中-公开
标题翻译：预测模型和方法诊断和评估冠状动脉疾病
公开(公告)号：WO2009049257A2
公开(公告)日：2009-04-16
申请号：PCT/US2008/079646
申请日：2008-10-10
申请人： CARDIO DX, INC. , ROSENBERG, Steve , DANIELS, Susan , ELASHOFF, Michael, R. , WINGROVE, James, A. , TINGLEY, Whittemore, G. , SEHNEERT, Amy, J. , PAONI, Nicholas, F.
发明人： ROSENBERG, Steve , DANIELS, Susan , ELASHOFF, Michael, R. , WINGROVE, James, A. , TINGLEY, Whittemore, G. , SEHNEERT, Amy, J. , PAONI, Nicholas, F.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/112 , C12Q2600/158
摘要： Biomarkers useful for diagnosing and assessing the extent of coronary artery disease (CAD) are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. In a preferred embodiment, the biomarkers are organized into clustered groups. The expression level of the biomarkers within a group are highly correlated to each other in normal and disease states. Expression values of genes chosen from each of two, three, four or five of the clustered gene groups, A, B, C, D, E may be used. Alternatively, expression values of genes chosen from the groups are combined into a metagene. Preferred biomarkers include S100A12, S100A8, S100A9, BCL2A1, and F5 (group A); XK, P62, and FECH (group B); TUBB2 (group C); IFNG, PDGFB, VSIG4, and TNF (group D); CSF3R, TLR5, CD46, and NCFl (group E); S100A12, S100A9, BCL2A1, TXN and CSTA (group I); OLIGl, 0LIG2, AD0RA3, CLC, and SLC29A1 (group II); and CBS and ARGl (group IV).
摘要翻译：提供用于诊断和评估冠状动脉疾病（CAD）程度的生物标志物，以及用于测量其表达的试剂盒。本发明还提供了基于生物标志物的预测模型以及计算机系统和用于对样品进行评分和任选分类的模型的软件实施例。在一个优选的实施方案中，生物标志物被组织成群集。组内生物标志物的表达水平在正常和疾病状态下彼此高度相关。可以使用从2,3,4或5个群集基因组A，B，C，D，E中的每一个中选择的基因的表达值。或者，将选自这些基因的基因的表达值组合成一种变应原。优选的生物标志物包括S100A12，S100A8，S100A9，BCL2A1和F5（A组）; XK，P62和FECH（B组）; TUBB2（C组）; IFNG，PDGFB，VSIG4和TNF（D组）; CSF3R，TLR5，CD46和NCF1（E组）; S100A12，S100A9，BCL2A1，TXN和CSTA（组I）; OLIG1，0LIG2，AD0RA3，CLC和SLC29A1（组II）; 和CBS和ARG1（第IV组）。

2. 发明申请

WO2009049257A9 PREDICTIVE MODELS AND METHODS FOR DIAGNOSING AND ASSESSING CORONARY ARTERY DISEASE 审中-公开
标题翻译：预测模型和方法诊断和评估冠状动脉疾病
公开(公告)号：WO2009049257A9
公开(公告)日：2009-10-29
申请号：PCT/US2008079646
申请日：2008-10-10
申请人： CARDIO DX INC , ROSENBERG STEVE , DANIELS SUSAN , ELASHOFF MICHAEL R , WINGROVE JAMES A , TINGLEY WHITTEMORE G , SEHNEERT AMY J , PAONI NICHOLAS F
发明人： ROSENBERG STEVE , DANIELS SUSAN , ELASHOFF MICHAEL R , WINGROVE JAMES A , TINGLEY WHITTEMORE G , SEHNEERT AMY J , PAONI NICHOLAS F
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/112 , C12Q2600/158
摘要： Biomarkers useful for diagnosing and assessing the extent of coronary artery disease (CAD) are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. In a preferred embodiment, the biomarkers are organized into clustered groups. The expression level of the biomarkers within a group are highly correlated to each other in normal and disease states. Expression values of genes chosen from each of two, three, four or five of the clustered gene groups, A, B, C, D, E may be used. Alternatively, expression values of genes chosen from the groups are combined into a metagene. Preferred biomarkers include S100A12, S100A8, S100A9, BCL2A1, and F5 (group A); XK, P62, and FECH (group B); TUBB2 (group C); IFNG, PDGFB, VSIG4, and TNF (group D); CSF3R, TLR5, CD46, and NCFl (group E); S100A12, S100A9, BCL2A1, TXN and CSTA (group I); OLIGl, 0LIG2, AD0RA3, CLC, and SLC29A1 (group II); and CBS and ARGl (group IV).
摘要翻译：提供用于诊断和评估冠状动脉疾病（CAD）程度的生物标志物，以及用于测量其表达的试剂盒。本发明还提供了基于生物标志物的预测模型以及计算机系统和用于对样品进行评分和任选分类的模型的软件实施例。在一个优选的实施方案中，生物标志物被组织成群集。组内生物标志物的表达水平在正常和疾病状态下彼此高度相关。可以使用从2,3,4或5个群集基因组A，B，C，D，E中的每一个中选择的基因的表达值。或者，将选自这些基因的基因的表达值组合成一种变应原。优选的生物标志物包括S100A12，S100A8，S100A9，BCL2A1和F5（A组）; XK，P62和FECH（B组）; TUBB2（C组）; IFNG，PDGFB，VSIG4和TNF（D组）; CSF3R，TLR5，CD46和NCF1（E组）; S100A12，S100A9，BCL2A1，TXN和CSTA（组I）; OLIG1，0LIG2，AD0RA3，CLC和SLC29A1（组II）; 和CBS和ARG1（第IV组）。

3. 发明申请

WO2009049257A3 PREDICTIVE MODELS AND METHODS FOR DIAGNOSING AND ASSESSING CORONARY ARTERY DISEASE 审中-公开
标题翻译：用于诊断和评估冠状动脉疾病的预测模型和方法
公开(公告)号：WO2009049257A3
公开(公告)日：2009-07-02
申请号：PCT/US2008079646
申请日：2008-10-10
申请人： CARDIO DX INC , ROSENBERG STEVE , DANIELS SUSAN , ELASHOFF MICHAEL R , WINGROVE JAMES A , TINGLEY WHITTEMORE G , SEHNEERT AMY J , PAONI NICHOLAS F
发明人： ROSENBERG STEVE , DANIELS SUSAN , ELASHOFF MICHAEL R , WINGROVE JAMES A , TINGLEY WHITTEMORE G , SEHNEERT AMY J , PAONI NICHOLAS F
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/112 , C12Q2600/158
摘要： Biomarkers useful for diagnosing and assessing the extent of coronary artery disease (CAD) are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. In a preferred embodiment, the biomarkers are organized into clustered groups. The expression level of the biomarkers within a group are highly correlated to each other in normal and disease states. Expression values of genes chosen from each of two, three, four or five of the clustered gene groups, A, B, C, D, E may be used. Alternatively, expression values of genes chosen from the groups are combined into a metagene. Preferred biomarkers include S100A12, S100A8, S100A9, BCL2A1, and F5 (group A); XK, P62, and FECH (group B); TUBB2 (group C); IFNG, PDGFB, VSIG4, and TNF (group D); CSF3R, TLR5, CD46, and NCFl (group E); S100A12, S100A9, BCL2A1, TXN and CSTA (group I); OLIGl, 0LIG2, AD0RA3, CLC, and SLC29A1 (group II); and CBS and ARGl (group IV).
摘要翻译：提供了有助于诊断和评估冠状动脉疾病（CAD）程度的生物标志物，以及用于测量其表达的试剂盒。本发明还提供了基于生物标志物的预测模型，以及用于评分和可选地分类样品的模型的计算机系统和软件实施方案。在优选的实施方案中，生物标志物被组织成聚集的组。一组中生物标志物的表达水平在正常和疾病状态下彼此高度相关。可以使用从两个，三个，四个或五个聚簇基因组A，B，C，D，E中的每一个中选择的基因的表达值。或者，选自组中的基因的表达值被组合成元源。优选的生物标志物包括S100A12，S100A8，S100A9，BCL2A1和F5（组A）; XK，P62和FECH（B组）; TUBB2（C组）; IFNG，PDGFB，VSIG4和TNF（D组）; CSF3R，TLR5，CD46和NCF1（组E）; S100A12，S100A9，BCL2A1，TXN和CSTA（组I）; OLIG1，0LIG2，AD0RA3，CLC和SLC29A1（组II）; 和CBS和ARG1（组IV）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式